An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

Completed

Conditions studied: Adenocarcinoma of Lung, Lung Neoplasm, Cancer of Lung, Lung Cancer, Pulmonary Cancer, EGFR Genes, ALK Genes

In brief

Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.

Key facts

Study ID

NCT02616211

Run by

Mayo Clinic

People needed

15

Starts

2014-10-01

Expected to finish

2019-12-01

Last updated by the study team

2020-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• Thoracic carcinoma tumors are positive for any targetable genetic alterations
• Have shown partial or no response, progression or recurrence while on or after gene targeted therapy by CT/PET scan
• Tumor is accessible for biopsy or surgery
• Expected life is 6 months or longer.

You may not qualify if…

• < 18 years
• Not able to communicate in English

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.